Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Saturday 23 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

Digital health concept

The NHS 10-Year Plan will only succeed if digital health mee...

The NHS 10-Year Plan defines three core pillars that are set to revolutionise how we receive care.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

R&D

Pipette and test tubes

Bridging ethics and efficacy in IRB review of vaccine trials

Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.

R&D

hVIVO Future of RSV research

Sponsored

Rethinking clinical research: The case for human challenge t...

R&D

A man sits in a laboratory, participant in a clinical trial

A patient-first mindset for change

May marks World Clinical Trials Day, bringing awareness to trials and the vital role they play.

Views & Analysis

UK Leaders Gileads Hilary Hutton-Squire on building trust with the NHS

UK Leaders: Gilead's Hilary Hutton-Squire on building trust ...

As general manager of Gilead UK and Ireland, Hilary Hutton-Squire has been at the forefront of bringing several innovative medicines to the NHS.

Views & Analysis

Staying on the cutting edge of oncology advances

Staying on the cutting edge of oncology advances

Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.

Views & Analysis

Coronavirus news

Coronavirus pharma news roundup - 13/03/2020

With coronavirus now declared a pandemic by WHO, all eyes are on pharma and other healthcare companies to develop solutions – but the industry isn’t immune to workforce and economic threats

Load more results

Sales & Marketing

Sales & Marketing

women in discussion

Sponsored

Company Profile: Inizio Ignite

Inizio Ignite is the global advisory partner for health and life sciences, encompassing connected expertise across its ecosystem.

Sales & Marketing

AI-powered decision engine visual

Sponsored

Solution Spotlight: Medscape One

Medscape One (M1) is a sophisticated, AI-powered decision engine designed to redefine HCP engagement.

Digital

Digital

Digital health concept

The NHS 10-Year Plan will only succeed if digital health mee...

The NHS 10-Year Plan defines three core pillars that are set to revolutionise how we receive care.

Digital

EHR

Closing the gap between diagnosis and treatment adherence wi...

For organisations, digital tools are increasingly critical to understanding and influencing patient behaviour between diagnosis and treatment.

Market Access

Market Access

The borders of Europe at night

Innovation beyond invention will bring novel medicines to Eu...

Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.

Market Access

pharma commercialisation concept - hcp and laptop and metrics

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Editor's Picks

BMS signs $15.2bn R&D alliance with China's Hengrui

UK Health Secretary resigns, sparking leadership speculation

Reports: Makary out, Diamantas in as FDA commissioner

EU agrees plan to tackle essential medicine shortages

Clock starts ticking on UK's single patient record plan

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Cancer cell and T-cell

CAR-NK cell therapies for solid tumours: Closing the gap bet...

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

Oncology

hcp and patients and dose optimisation in clinic with nurses

Dose optimisation in oncology: Insights from AACR 2026 and i...

Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.

Oncology

Precision medicine, DNA on target

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Patients

Patients

pharmaphorum podcast Episode, 260 - Ramy Younes, Boehringer Ingelheim

The cardio-renal-metabolic space and obesity as a chronic di...

The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.

Patients

A hand grabs and breaks a DNA chain to represent biohacking

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Patients

Hands in a circle point to the middle where EU stars are, blue background

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

R&D

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

R&D

Pipette and test tubes

Bridging ethics and efficacy in IRB review of vaccine trials

Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.

R&D

hVIVO Future of RSV research

Sponsored

Rethinking clinical research: The case for human challenge t...

Editor's Picks

BMS signs $15.2bn R&D alliance with China's Hengrui

UK Health Secretary resigns, sparking leadership speculation

Reports: Makary out, Diamantas in as FDA commissioner

EU agrees plan to tackle essential medicine shortages

Clock starts ticking on UK's single patient record plan

News

GBL joins CVC in €10.7bn takeover bid for Recordati

GBL joins CVC in €10.7bn takeover bid for Recordati

A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company